

## Appendix E. Hepatitis C prevalence by region and country

### Prevalence of anti-HCV by Global Burden of Disease Regions

Region	Anti-HCV prevalence estimates (%)	95% Confidence Interval
Central Asia	3.8	3.0-4.5
East Asia	3.7	3.1-4.5
North Africa & Middle East	3.6	3.2-4.1
South Asia	3.4	2.6-4.4
Eastern Europe	2.9	2.3-3.5
West Sub-Saharan Africa	2.8	2.4-3.3
Australasia	2.7	2.2-3.2
Oceania	2.6	2.1-3.1
Central Europe	2.4	2.0-2.8
Western Europe	2.4	2.2-2.7
Central Sub-Saharan Africa	2.3	1.6-3.1
Caribbean	2.1	1.6-2.6
South Sub-Saharan Africa	2.1	1.7-2.5
Andean Latin America	2.0	1.4-2.7
East Sub-Saharan Africa	2.0	1.6-2.4
South East Asia	2.0	1.7-2.3
Central Latin America	1.6	1.3-1.9
Southern Latin America	1.6	1.1-2.2
High income Asia Pacific	1.4	1.2-1.5
High Income North America	1.3	1.1-1.6
Tropical Latin America	1.2	1.0-1.4

Source: Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. *Hepatology* 2013;57:1333-1342.

**List of countries with estimated anti-HCV prevalence  $\geq 3\%$  (2010)**

Country	Anti-HCV (%)
Angola	5
Armenia	4
Azerbaijan	4
Bolivia	4.7
Burkina Faso	5.2
Burundi	11.3
Cambodia	4.1
Cameroon	13.8
Cape Verde	3
Chad	5
Congo	5.5
Democratic Republic of Congo	6.4
Egypt	14
Estonia	5
Gabon	9.2
Georgia	6.7
Grenada	5
Guinea	5.5
Guinea-Bissau	4.7
Haiti	4.4
Indonesia	3.9
Iraq	3.21
Italy	3.2
Ivory Coast	3.3
Kazakhstan	3.2
Kuwait	3.1
Kyrgyzstan	4
Liberia	3
Malawi	6.8
Mali	3.3
Mongolia	10.7
Mozambique	3.2
Niger	3.2
Pakistan	5.9
Romania	4.5
Russia	4.1
Rwanda	4.9
Sao Tome and Principe	10
Senegal	3
Tajikistan	4
Togo	3.3
Trinidad and Tobago	3.9
Turkmenistan	4
Uganda	6.6
Ukraine	4
United Republic of Tanzania	3.2
Uzbekistan	6.5
Western Sahara	3

Source: Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-115.